$BCRX News

BioCryst to Report Third Quarter 2026 Financial Results on November 4

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

FDA Approves BioCryst Pharma’s sNDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Adults And Adolescents Aged 12 Years And Older

BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13

Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?

Biopharma Stock With Layers of Technical Support in Place

BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story

RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11

CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio

Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target

BioCryst to Present at Upcoming Investor Conference

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan

BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen